Termine Termine

Stöbern Sie in unserem bunten und spannenden Veranstaltungsprogramm. Hier finden Sie auch regelmäßig unsere Messebeteiligungen und Tage der offenen Tür, an denen Sie sich über unser Studienangebot informieren können.

18.01.2018
16:00 bis 18:00 Uhr
RheinAhrCampus Raum F125
RheinAhrCampus
Joseph-Rovan-Allee 2
53424 Remagen

zurück zur Liste

Data Science und Maschinelles Lernen - Vortragsreihe am RheinAhrCampus

Vortragsreihe am RheinAhrCampus:
Data Science und Maschinelles Lernen

Thomas Gerlach
Analytical Scientist
UCB BIOSCIENCES GmbH

auf Einladung von Prof. Dr. Maik Kschischo

Donnerstag, 18. Januar 2018, 16.00-17.00 Uhr, Raum F125, Eintritt frei                       

Predicting comorbidities of epilepsy patients using big data from Electronic Health Records combined with biomedical knowledge

Abstract:
Epilepsy is a complex brain disorder characterized by repetitive seizure events. Epilepsy patients often suffer from various and severe physical and psychological comorbidities. While general comorbidity prevalence and incidences can be estimated from epidemiological data, such an approach does not take into account that actual patient specific risks can depend on various individual factors, including medication. This motivates to develop a machine learning approach for predicting individual comorbidities. To address these needs we used Big Data from electronic health records (~100 Million raw observations), which provide a time resolved view on an individual's disease and medication history. A specific contribution of this work is an integration of these data with information from 14 biomedical sources (DisGeNET, TTD, KEGG, Wiki Pathways, DrugBank, SIDER, Gene Ontology, Human Protein Atlas) to capture putative biological effects of observed diseases and applied medications. In consequence we extracted >165,000 features describing the longitudinal patient journey of >10,000 adult epilepsy patients. We used maximum-relevance-minimum-redundancy feature selection in combination with Random Survival Forests (RSF) for predicting the risk of 9 major comorbidities after first epilepsy diagnosis with high cross-validated C-indices of 76 - 89% and analyzed the influence of medications on the risk to develop specific comorbidities. Altogether we see our work as a first step towards earlier detection and better prevention of common comorbidities of epilepsy patients.